Resmetirom

Resmetirom
Clinical data
Trade names	Rezdiffra
Other names	MGL-3196
AHFS/Drugs.com	Monograph
MedlinePlus	a624021
License data	US DailyMed: Resmetirom;
Routes of; administration	By mouth
ATC code	A05BA11 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name 2-[3,5-dichloro-4-[(6-oxo-5-propan-2-yl-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile;
CAS Number	920509-32-6;
PubChem CID	15981237;
DrugBank	DB12914;
UNII	RE0V0T1ES0;
KEGG	D11602;
ChEMBL	ChEMBL3261331;
CompTox Dashboard (EPA)	DTXSID601352610 ;
Chemical and physical data
Formula	C17H12Cl2N6O4
Molar mass	435.22 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)C1=CC(=NNC1=O)OC2=C(C=C(C=C2Cl)N3C(=O)NC(=O)C(=N3)C#N)Cl;
	InChI InChI=1S/C17H12Cl2N6O4/c1-7(2)9-5-13(22-23-15(9)26)29-14-10(18)3-8(4-11(14)19)25-17(28)21-16(27)12(6-20)24-25/h3-5,7H,1-2H3,(H,23,26)(H,21,27,28); Key:FDBYIYFVSAHJLY-UHFFFAOYSA-N;

Resmetirom, sold under the brand name Rezdiffra, is a medication used to treat a form of fatty liver disease. Specifically it is used in the treatment of noncirrhotic metabolic dysfunction associated steatohepatitis (MASH) (formerly known as nonalcoholic steatohepatitis NASH). It is structurally similar to the thyroid hormone triiodothyronine and acts as an agonist of the thyroid hormone receptor beta (NR1A2).

The most common side effects include diarrhea and nausea.

Resmetirom was approved for medical use in the US in March 2024, and in the European Union in August 2025. The US Food and Drug Administration considers it to be a first-in-class medication.